Voxel Bundle
Who Really Owns Voxel Company?
In the rapidly evolving healthcare sector, understanding a company's ownership is paramount. With Diagnostyka's successful IPO in February 2025, exceeding €1 billion in market capitalization, the spotlight is on companies like Voxel S.A. to see how they will compete. But who exactly controls the strategic direction of this key player in Polish medical diagnostics?
Voxel S.A., a Polish healthcare provider, has demonstrated impressive growth, with revenues and earnings increasing significantly in 2024. Knowing Voxel SWOT Analysis and who holds the reins of Voxel ownership is critical for investors and stakeholders alike. This analysis will uncover the key Voxel shareholders, from its inception in 2005 to its current status as a publicly traded entity on the Warsaw Stock Exchange, examining the influence of the Voxel parent company and major investors.
Who Founded Voxel?
The genesis of the Voxel Company, known as Voxel S.A., traces back to its incorporation in 2005 in Krakow, Poland. The company's inception was driven by a vision to establish a network of diagnostic imaging laboratories, aiming to enhance access to high-quality medical tests. While the precise details of the founders' identities and initial equity distribution remain unavailable in the provided information, the company's early trajectory involved securing funding to fuel its growth within the Polish healthcare sector.
Voxel S.A. initiated its operations with the goal of expanding access to advanced medical diagnostics, establishing a network of laboratories. The company's early financial strategy included securing capital to support its expansion plans. The initial ownership structure likely involved the founders, potentially with angel investments or contributions from friends and family, setting the stage for future institutional backing.
Early financial records show that Voxel S.A. had a Post-IPO funding round in November 2008, raising $4.27 million from institutional investors including Pro Partners and RTAventures. This suggests that the initial ownership structure involved the founders, possibly with angel investors or contributions from friends and family, followed by an IPO and subsequent institutional backing to fuel its early growth and expansion in the Polish healthcare market. The company's initial focus was on building a network of diagnostic imaging laboratories.
Founding Year
Voxel Company was established in 2005 in Krakow, Poland.
Initial Vision
The company's primary goal was to create a network of diagnostic imaging laboratories.
Early Funding
Voxel S.A. raised $4.27 million in a Post-IPO funding round in November 2008.
Key Investors
Institutional investors like Pro Partners and RTAventures participated in the early funding rounds.
Ownership Structure
Early ownership likely included founders, angel investors, and later, institutional investors.
Market Focus
The company initially focused on expanding within the Polish healthcare market.
Who Owns Voxel?
The ownership of Voxel Company has evolved since its inception. Initially, the founders likely held a significant stake, potentially with angel investors or contributions from friends and family. Subsequent funding rounds, such as the $4.27 million raised in November 2008, brought in institutional investors like Pro Partners and RTAventures. The Voxel Group's shareholders include these institutional investors, along with any individuals or entities that acquired shares through the IPO or subsequent offerings. To understand the full scope of Voxel ownership, including the Voxel parent company, a review of the company's financial reports and shareholder disclosures is necessary. For more information, you can read a Brief History of Voxel.
- The company was founded in 2005 in Krakow, Poland.
- Early investors included institutional entities like Pro Partners and RTAventures.
- The initial focus was on building a network of diagnostic imaging laboratories.
- The ownership structure has evolved since the initial founding.
Voxel SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Voxel’s Ownership Changed Over Time?
The Voxel Company, a publicly traded entity, saw its shares listed on the Warsaw Stock Exchange on October 11, 2011. The company's ownership structure has evolved since then, with key stakeholders emerging over time. Understanding the shifts in ownership provides insights into the company's strategic direction and financial performance. The most recent data available as of June 11, 2025, shows the stock price at $44.23, with a market capitalization of $465 million, and 10.5 million shares outstanding.
A significant aspect of Voxel's ownership involves its major shareholders. Voxel International S.a.r.l., based in Luxembourg, holds a substantial stake, and institutional investors also play a crucial role. It's important to differentiate between Voxel S.A., the Polish healthcare provider, and another company named 'Voxel'. On February 29, 2024, Amadeus IT Group, S.A. acquired 100% ownership of a different 'Voxel' for €125.5 million, which is a provider of electronic invoicing and B2B electronic payments for the travel and hospitality industry. This highlights the importance of distinguishing between the two entities.
| Shareholder | Stake | Shares |
|---|---|---|
| Voxel International S.a.r.l. | 37.40% | 5,184,856 |
| TFI PZU SA (as of June 30, 2024) | 14.60% | 1,533,479 |
| Allianz Polska S.A. Open Pension Fund (as of June 30, 2024) | 6.50% | 682,645 |
As of December 31, 2024, Voxel S.A. demonstrated a strong financial performance, with a Return on Equity (ROE) of 26.75%. The company's revenue in 2024 was PLN 507.77 million (approximately USD 140 million), reflecting a 19.71% increase compared to the previous year. The net income for the same period was PLN 101.50 million. For those interested in the company's financial structure, you can read about the Revenue Streams & Business Model of Voxel.
Key Takeaways on Voxel Ownership
Voxel S.A. is a publicly traded company, with key shareholders including Voxel International S.a.r.l. and several institutional investors.
- The company's stock price was $44.23 as of June 11, 2025.
- Voxel's ROE was 26.75% as of December 31, 2024.
- Distinguish between Voxel S.A. and other companies with similar names.
- The company's revenue in 2024 was PLN 507.77 million.
Voxel PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Voxel’s Board?
The corporate governance structure of the Voxel Company is composed of a Management Board and a Supervisory Board. The Management Board, with a term of four years, had its current members appointed on August 19, 2020. The Supervisory Board members serve five-year terms, with the current term starting on June 29, 2021. Wojciech Napiórkowski was appointed to the Supervisory Board on June 28, 2024, and became the Chair of the Audit Committee. The Audit Committee also includes Martyna Liszka-Białek and Jakub Kowalik.
On June 28, 2024, the Ordinary General Meeting approved the company's remuneration policy for the Management Board and Supervisory Board, including information on share-based incentive programs. There is no readily available information regarding recent proxy battles, activist investor campaigns, or governance controversies that have significantly impacted decision-making within Voxel S.A. The company's structure and decision-making processes are primarily influenced by these boards and their respective committees.
| Board | Term Start Date | Notes |
|---|---|---|
| Management Board | August 19, 2020 | Four-year term |
| Supervisory Board | June 29, 2021 | Five-year term |
| Audit Committee | June 28, 2024 | Chaired by Wojciech Napiórkowski |
Voxel International S.a.r.l., based in Luxembourg, holds 37.40% of the shares, representing 5,184,856 votes. With a total of 10,502,600 shares and 13,502,700 votes, the voting rights per share may vary across different share series. This significant Voxel ownership by Voxel International S.a.r.l. indicates substantial influence over the company's strategic direction. To understand more about the company's target market, you can read about it in this article: Target Market of Voxel.
Key Takeaways on Voxel Ownership
The Voxel Group's governance is overseen by a Management Board and a Supervisory Board. The largest Voxel shareholders, Voxel International S.a.r.l., holds a significant stake. Understanding the board structure and major shareholders is crucial for assessing the company's strategic direction.
- Management Board members appointed on August 19, 2020.
- Supervisory Board members appointed on June 29, 2021.
- Wojciech Napiórkowski chairs the Audit Committee.
- Voxel International S.a.r.l. holds 37.40% of the shares.
Voxel Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Voxel’s Ownership Landscape?
Over the past 3-5 years, the Voxel Company has demonstrated significant financial growth and business consolidation, particularly following the COVID-19 pandemic. This growth is largely attributed to an increase in diagnostic procedures like CT and MRI scans, supported by favorable reimbursement policies from the National Health Fund (NFZ). Projections for 2024-2026 anticipate an 8-11% growth in sales, driven by organic expansion in diagnostic and therapeutic procedures, along with enhanced service reimbursement policies. The Voxel Group is also experiencing changes within its operational structure.
A key development is the disinvestment in the non-rental COVID-19 diagnostic segment (Vito-Med sales) starting November 1, 2023. This strategic move is expected to positively influence operating margins, with a projected 2-3% improvement in the EBIT margin during 2024-2025. These changes reflect the company's focus on optimizing its business model and improving profitability. The Voxel Company continues to evolve and adapt to market dynamics and shifts in healthcare demands.
| Ownership Details | As of | Stakeholder |
|---|---|---|
| Increased Stake | June 30, 2024 | TFI PZU SA (to 14.60%) |
| Increased Holding | June 30, 2024 | Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA |
| Dividend Information | September 19, 2024 | Annual dividend of 2.78 PLN per share, with a yield of 1.82% |
Institutional investors continue to hold a significant presence within the Voxel ownership structure. The company has a dividend policy aimed at sharing profits with Voxel shareholders, with the Management Board intending to recommend allocating at least 50% of the net profit for dividends annually. The Polish healthcare market is experiencing transformative growth, driven by digital health solutions and government support, with telemedicine and AI integrations enhancing accessibility and efficiency. The medical device market in Poland is projected to expand with a 5.9% CAGR from 2024-2029. For more insights into the competitive environment, consider reading about the Competitors Landscape of Voxel.
Voxel's Financial Performance
The company's revenue growth is influenced by the increasing number of diagnostic procedures. The company's sales are expected to grow between 8-11% between 2024 and 2026. The company's dividend was 2.78 PLN per share, with a yield of 1.82% as of September 19, 2024.
Ownership Changes
Institutional investors are key stakeholders. TFI PZU SA increased its stake to 14.60% as of June 30, 2024. Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA also increased its holding. The Voxel parent company is seeing changes in its shareholder structure.
Strategic Moves
Disinvestment in the non-rental COVID-19 diagnostic segment (Vito-Med sales) started November 1, 2023. This strategic move is projected to improve the EBIT margin by 2-3% in 2024-2025. The company is focusing on core diagnostic and therapeutic procedures.
Market Dynamics
The Polish healthcare market is experiencing growth driven by digital health solutions and government support. The medical device market in Poland is projected to expand with a 5.9% CAGR from 2024-2029. These trends create a positive environment for Voxel Company's growth.
Voxel Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Voxel Company?
- What is Competitive Landscape of Voxel Company?
- What is Growth Strategy and Future Prospects of Voxel Company?
- How Does Voxel Company Work?
- What is Sales and Marketing Strategy of Voxel Company?
- What is Brief History of Voxel Company?
- What is Customer Demographics and Target Market of Voxel Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.